Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 12/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31320196 | 1.00 | KIF18A (0.46) | KIF18AAKT1ATMPIK3CBPIK3CA | |
| SCHEMBL30637270 | 0.85 | RBP4 (0.45) | KIF18AAKT1ATMPIK3CDPIK3CG | |
| SCHEMBL31320207 | 0.85 | KIF18A (0.45) | KIF18AAKT1ATMPIK3CBPIK3CA | |
| SCHEMBL22122546 | 0.77 | GRIN2D (0.46) | KIF18AATMPIK3CBPIK3CAPIK3CD | |
| SCHEMBL22152109 | 0.77 | GRIN2D (0.46) | KIF18AATMPIK3CBPIK3CAPIK3CD | |
| SCHEMBL22122544 | 0.77 | GRIN2D (0.46) | KIF18AATMPIK3CBPIK3CAPIK3CD | |
| SCHEMBL30615819 | 0.76 | RBP4 (0.46) | — | |
| SCHEMBL2551286 | 0.75 | ALDH1A1 (0.42) | — | |
| SCHEMBL30615940 | 0.74 | RBP4 (0.43) | KIF18A | |
| SCHEMBL30615956 | 0.74 | KIF18A (0.60) | KIF18A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250264-A1 | KIF18A INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-08-07 | — | — | US | disclosed |
| EP-4509505-A1 | KIF18A INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250264-A1 | KIF18A INHIBITOR AND USE THEREOF | KIF18A, KIF18B, KIF15 | KIF18A 1/4885AKT1 1069/4885ATM 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.